Day One Biopharma Files 8-K

Ticker: DAWN · Form: 8-K · Filed: Nov 24, 2025 · CIK: 1845337

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Day One Biopharma filed an 8-K, check for updates.

AI Summary

On November 24, 2025, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that Day One Biopharmaceuticals has made a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K without immediate disclosed material events, suggesting low immediate risk.

Key Players & Entities

FAQ

What specific event triggered this 8-K filing?

The filing indicates it is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, but the specific triggering event is not detailed in the provided excerpt.

When was the earliest event reported in this filing?

The earliest event reported is dated November 24, 2025.

What is the principal executive office address for Day One Biopharmaceuticals, Inc.?

The principal executive office is located at 1800 Sierra Point Parkway, Suite 200, Brisbane, California 94005.

What is the SEC file number for Day One Biopharmaceuticals, Inc.?

The SEC file number is 001-40431.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

Filing Stats: 1,192 words · 5 min read · ~4 pages · Grade level 11.6 · Accepted 2025-11-24 08:09:14

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 24, 2025 99.2 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements we make regarding our ability to obtain regulatory approval for, and commercialize, tovorafenib, our future results of operations and financial position, business strategy, market size, potential growth opportunities, nonclinical and clinical development activities, efficacy and safety profile of our product candidates, potential therapeutic benefits and economic value of our product candidates, our ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of nonclinical studies and clinical trials, commercial collaboration with third parties, and our ability to recognize milestone and royalty payments from commercialization agreements, the expected impact of global business or macroeconomic conditions, including as a result of inflation, rising interest rates, cybersecurity incidents, instability in the global banking system, government shutdowns, uncertainty with respect to the federal budget, and geopolitical conflicts including the conflicts in Israel and Ukraine, on our operations, and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates. Such risks and uncertainties include, among others, the risks identified in the Company's filings with the Securities and Exchange Commission ("SEC"), including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 4, 2025, and other reports as filed with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obliga

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: November 24, 2025 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing